Published in Curr Opin HIV AIDS on September 01, 2010
Genetic and neutralization sensitivity of diverse HIV-1 env clones from chronically infected patients in China. J Biol Chem (2011) 1.33
AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccines. PLoS Med (2010) 0.89
Health research capacity development in low and middle income countries: reality or rhetoric? A systematic meta-narrative review of the qualitative literature. BMJ Open (2017) 0.85
Improving ethical and participatory practice for marginalized populations in biomedical HIV prevention trials: lessons from Thailand. PLoS One (2014) 0.82
An HIV Vaccine for South-East Asia-Opportunities and Challenges. Vaccines (Basel) (2013) 0.77
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis (2006) 7.98
The changing face of HIV in China. Nature (2008) 3.39
Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol (2008) 1.83
A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr (2007) 1.39
Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial. J Virol (2008) 1.38
A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses (2009) 1.35
A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS (2006) 1.33
Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine (2009) 1.24
High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40). J Immunol (2009) 1.22
Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood. PLoS Pathog (2008) 1.10
A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules. ACS Nano (2009) 1.02
A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine. AIDS Res Hum Retroviruses (2008) 1.01
Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. Vaccine (2009) 0.98
Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes. Vaccine (2008) 0.98
HIV mucosal vaccine: nasal immunization with rBCG-V3J1 induces a long term V3J1 peptide-specific neutralizing immunity in Th1- and Th2-deficient conditions. J Immunol (2001) 0.97
Evaluation of recombinant influenza virus-simian immunodeficiency virus vaccines in macaques. J Virol (2009) 0.96
A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. PLoS One (2009) 0.95
Surveillance of subtype and genetic variation of the circulating strains of HIV-1 in Thailand. Southeast Asian J Trop Med Public Health (2007) 0.93
Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques. Vaccine (2005) 0.92
Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B. Vaccine (2008) 0.88
HIV vaccine trials in India. Nat Biotechnol (2008) 0.85
HIV vaccine research in Thailand: lessons learned. Expert Rev Vaccines (2008) 0.84
Adjuvant effects of plasmid-generated hairpin RNA molecules on DNA vaccination. Vaccine (2007) 0.84
Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. AIDS Res Hum Retroviruses (2009) 0.81
Development of a candidate DNA/MVA HIV-1 subtype C vaccine for India. Vaccine (2006) 0.81
China and Thailand to start trials of AIDS vaccines. BMJ (1993) 0.79
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med (2015) 15.06
Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med (2015) 7.99
Grand challenges in chronic non-communicable diseases. Nature (2007) 7.86
Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33
Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS (2011) 6.26
The case for boosting infant male circumcision in the face of rising heterosexual transmission of HIV. Med J Aust (2010) 5.94
Relation between HIV viral load and infectiousness: a model-based analysis. Lancet (2008) 5.74
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS (2006) 5.31
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr (2006) 4.71
Medicine. The need for a global HIV vaccine enterprise. Science (2003) 4.70
Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. PLoS Med (2005) 4.65
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med (2008) 3.71
Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis. N Engl J Med (2016) 3.59
Notch pathway molecules are essential for the maintenance, but not the generation, of mammalian neural stem cells. Genes Dev (2002) 3.55
The changing face of HIV in China. Nature (2008) 3.39
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis (2009) 3.32
Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J Exp Med (2002) 3.24
Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res (2013) 3.20
Hzf Determines cell survival upon genotoxic stress by modulating p53 transactivation. Cell (2007) 3.20
The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr (2005) 3.18
Characterization of CD4(+) CTLs ex vivo. J Immunol (2002) 3.10
Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol (2005) 3.03
Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial. AIDS (2005) 2.94
Short-term clinical disease progression in HIV-infected patients receiving combination antiretroviral therapy: results from the TREAT Asia HIV observational database. Clin Infect Dis (2009) 2.89
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89
HIV prevention research in a resource-limited setting: the experience of planning a trial in Cambodia. Lancet (2005) 2.83
Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr (2014) 2.79
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol (2012) 2.74
Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution. J Virol (2006) 2.70
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A (2013) 2.69
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis (2012) 2.68
Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc Natl Acad Sci U S A (2012) 2.64
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS (2007) 2.58
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med (2014) 2.47
Hepatitis C virus infection in former commercial plasma/blood donors in rural Shanxi Province, China: the China Integrated Programs for Research on AIDS. J Infect Dis (2005) 2.47
A comprehensive mapping of HIV-1 genotypes in various risk groups and regions across China based on a nationwide molecular epidemiologic survey. PLoS One (2012) 2.44
No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet (2004) 2.43
Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis (2010) 2.41
Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-11): a national observational cohort study. Lancet (2012) 2.41
Stage-dependent production and release of histidine-rich protein 2 by Plasmodium falciparum. Trans R Soc Trop Med Hyg (2005) 2.38
Dominance of HIV-1 subtype CRF01_AE in sexually acquired cases leads to a new epidemic in Yunnan province of China. PLoS Med (2006) 2.37
Co-infection with HIV and hepatitis C virus in former plasma/blood donors: challenge for patient care in rural China. AIDS (2006) 2.36
Syphilis among female sex workers in southwestern China: potential for HIV transmission. Sex Transm Dis (2006) 2.34
Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis (2011) 2.34
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS (2007) 2.27
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med (2009) 2.21
Hematopoietic stem cell and progenitor defects in Sca-1/Ly-6A-null mice. Blood (2002) 2.15
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis (2010) 2.14
Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis (2009) 2.08
HIV prevention: Bring safe sex to China. Nature (2012) 2.05
Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr (2004) 2.05
Predictors of disease progression in HIV infection: a review. AIDS Res Ther (2007) 2.05
International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One (2009) 2.03
Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. Lancet Infect Dis (2012) 2.01
Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis (2004) 2.01
Relationship between syphilis and HIV infections among men who have sex with men in Beijing, China. Sex Transm Dis (2007) 2.00
Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine (2005) 1.96
Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol (2013) 1.95
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses (2012) 1.94
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One (2013) 1.94
Tracing the origin and history of HIV-1 subtype B' epidemic by near full-length genome analyses. AIDS (2012) 1.89
Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA (2002) 1.88
Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med (2014) 1.87
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? AIDS (2004) 1.85
Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol (2008) 1.83
Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS (2003) 1.80
Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis (2005) 1.80
Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy. J Infect Dis (2009) 1.79
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis (2013) 1.78
The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol (2012) 1.75
Young women engaged in sex work in Phnom Penh, Cambodia, have high incidence of HIV and sexually transmitted infections, and amphetamine-type stimulant use: new challenges to HIV prevention and risk. Sex Transm Dis (2011) 1.74
Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem (2008) 1.74
The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials (2002) 1.73
Association between Vgamma2Vdelta2 T cells and disease progression after infection with closely related strains of HIV in China. Clin Infect Dis (2008) 1.72
Gender gaps in life expectancy: generalized trends and negative associations with development indices in OECD countries. Eur J Public Health (2012) 1.69
The prevalence of transmitted antiretroviral drug resistance in treatment-naive HIV-infected individuals in China. J Acquir Immune Defic Syndr (2010) 1.67
Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis (2009) 1.66
Untested and undiagnosed: barriers to HIV testing among men who have sex with men, Beijing, China. Sex Transm Infect (2011) 1.63
Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS (2004) 1.62
A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis (2005) 1.62
Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS (2004) 1.61
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis (2015) 1.61
Impact of thymectomy on the peripheral T cell pool in rhesus macaques before and after infection with simian immunodeficiency virus. Eur J Immunol (2005) 1.60
Incidence of HIV-1, syphilis, hepatitis B, and hepatitis C virus infections and predictors associated with retention in a 12-month follow-up study among men who have sex with men in Beijing, China. J Acquir Immune Defic Syndr (2009) 1.60